FDA Inspection
Lilly France S.A.S.Lilly France S.A.S. – FDA Inspection, Feb 19, 2019
Record Details
This FDA Inspection record concerns Lilly France S.A.S., with an inspection on February 19, 2019, issued by the Office of Inspections and Investigations, covering human drugs.
View Company Profile
ID · 107930e4-af02-49fc-acbe-092ab003f224
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1081382
- FDA center
- Human Drugs
- Project area
- New Drug Evaluation
- Outcome
- Form 483 issued
FDA Citations
3- 21 CFR 211.194(c)Testing and standardization of standards et. al.
- 21 CFR 211.63Equipment Design, Size and Location
- 21 CFR 211.67(a)Cleaning / Sanitizing / Maintenance
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Lilly France S.A.S.
8| Date | Classification | Office | Project area |
|---|---|---|---|
| September 29, 2023 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 15, 2021 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 16, 2020 | NAI | Center for Devices and Radiological Health | Postmarket Assurance: Devices |
| August 28, 2018 | Not classified | Office of Inspections and Investigations | |
| April 4, 2017 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Lilly France S.A.S.
- FDA Inspection 1299456 - 2023-09-29
- FDA Inspection 1180181 - 2021-01-15
- FDA Inspection 1117961 - 2020-01-16
- FDA Inspection 1063854 - 2018-08-28
- FDA Inspection 1020863 - 2017-04-04
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.